fenofibrate has been researched along with Kidney Diseases in 36 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients." | 8.02 | Effects of fenofibrate therapy on renal function in primary gout patients. ( Chen, Y; Cheng, X; Cui, L; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Ma, L; Merriman, TR; Ren, W; Sun, W; Wang, C; Wang, X; Yuan, X; Zhang, H, 2021) |
| "Fenofibrate was injected at 45 min before renal ischemia." | 5.42 | Protective effect of Fenofibrate in renal ischemia reperfusion injury: Involved in suppressing kinase 2 (JAK2)/transcription 3 (STAT3)/p53 signaling activation. ( Feng, M; Liang, PF; Liu, SY; Lv, J; Wang, X; Xu, AP; Zhang, LL, 2015) |
| "Fenofibrate (160 mg/d) was added." | 5.40 | Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia. ( Beltrán, LM; Puig, JG; Salgueiro, G; Torres, RJ, 2014) |
| "To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients." | 4.02 | Effects of fenofibrate therapy on renal function in primary gout patients. ( Chen, Y; Cheng, X; Cui, L; Han, L; He, Y; Ji, A; Ji, X; Li, C; Li, H; Li, X; Liu, Z; Lu, J; Ma, L; Merriman, TR; Ren, W; Sun, W; Wang, C; Wang, X; Yuan, X; Zhang, H, 2021) |
| " In the salt-loaded spontaneously hypertensive stroke-prone rat (SHRSP), a model of cardiac hypertrophy and nephropathy that shows mitochondrial alterations in the myocardium, we evaluated the cardiorenal effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist that acts by modulating mitochondrial and peroxisomal fatty acid oxidation." | 3.88 | Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. ( Abbate, M; Castiglioni, L; Crestani, M; Fiaschè, M; Fiordaliso, F; Foray, C; Gelosa, P; Giudici, M; Guerrini, U; Mitro, N; Pignieri, A; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C, 2018) |
| "Fenofibrate therapy was initiated for a 60-year old Hispanic man with stage 4 chronic kidney disease (CKD) for the treatment of hypertriglyceridemia." | 3.74 | Elevated serum creatinine levels associated with fenofibrate therapy. ( Anderson, J; Griego, J; McQuade, CR; Pai, AB, 2008) |
| " The authors treated a 36-year-old woman with LPG and exhibiting a nephrotic syndrome using an intensive lipid-lowering therapy consisting of fenofibrate (300 mg), niceritrol (750 mg), ethyl-icosapentate (1,800 mg), and probucol (500 mg)." | 3.72 | Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. ( Hotta, O; Ieiri, N; Taguma, Y, 2003) |
| "Fenofibrate has also been shown to suppress arrhythmias in isolated rat hearts subjected to ischemic/reperfusion-induced cardiac injury." | 2.61 | Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits. ( Alsayari, A; Balakumar, P; Dhanaraj, SA; Mahadevan, N; Muhsinah, AB; Sambathkumar, R; Venkateswaramurthy, N, 2019) |
| "Fenofibrate has been used for the management of atherogenic dyslipidaemia for many years." | 2.49 | Fenofibrate and the kidney: an overview. ( Elisaf, MS; Florentin, M; Kostapanos, MS, 2013) |
| "Fenofibrate-associated nephrotoxicity is an underrecognized adverse effect that is being reported with increasing frequency in the medical literature." | 2.49 | Fenofibrate-associated nephrotoxicity: a review of current evidence. ( Attridge, RL; Frei, CR; Koeller, J; Linn, WD; Ryan, L, 2013) |
| "Fenofibrate was injected at 45 min before renal ischemia." | 1.42 | Protective effect of Fenofibrate in renal ischemia reperfusion injury: Involved in suppressing kinase 2 (JAK2)/transcription 3 (STAT3)/p53 signaling activation. ( Feng, M; Liang, PF; Liu, SY; Lv, J; Wang, X; Xu, AP; Zhang, LL, 2015) |
| "Fenofibrate (160 mg/d) was added." | 1.40 | Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia. ( Beltrán, LM; Puig, JG; Salgueiro, G; Torres, RJ, 2014) |
| " We also observed a joint effect of high statin dosage and renal disease (p = 0." | 1.34 | Risk factors for statin-associated rhabdomyolysis. ( Andrade, SE; Blough, D; Burgess, M; Chan, KA; Graham, D; La Grenade, L; Platt, R; Schech, S; Shatin, D; Staffa, J; Stergachis, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 11 (30.56) | 29.6817 |
| 2010's | 22 (61.11) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Chauhan, K | 1 |
| Nadkarni, GN | 1 |
| Debnath, N | 1 |
| Chan, L | 1 |
| Saha, A | 1 |
| Garg, AX | 1 |
| Parikh, CR | 1 |
| Coca, SG | 1 |
| Li, X | 1 |
| Sun, W | 1 |
| Lu, J | 1 |
| He, Y | 1 |
| Chen, Y | 1 |
| Ren, W | 1 |
| Cui, L | 1 |
| Liu, Z | 1 |
| Wang, C | 1 |
| Wang, X | 2 |
| Ma, L | 1 |
| Cheng, X | 1 |
| Han, L | 1 |
| Li, H | 1 |
| Zhang, H | 1 |
| Yuan, X | 1 |
| Ji, X | 2 |
| Ji, A | 1 |
| Merriman, TR | 1 |
| Li, C | 2 |
| Cheng, L | 1 |
| Ge, M | 1 |
| Lan, Z | 1 |
| Ma, Z | 1 |
| Chi, W | 1 |
| Kuang, W | 1 |
| Sun, K | 1 |
| Zhao, X | 1 |
| Liu, Y | 2 |
| Feng, Y | 1 |
| Huang, Y | 1 |
| Luo, M | 1 |
| Li, L | 1 |
| Zhang, B | 1 |
| Hu, X | 1 |
| Xu, L | 1 |
| Liu, X | 2 |
| Huo, Y | 1 |
| Deng, H | 1 |
| Yang, J | 2 |
| Xi, Q | 1 |
| Zhang, Y | 2 |
| Siegenthaler, JA | 1 |
| Chen, L | 2 |
| Castiglioni, L | 2 |
| Pignieri, A | 2 |
| Fiaschè, M | 1 |
| Giudici, M | 1 |
| Crestani, M | 1 |
| Mitro, N | 1 |
| Abbate, M | 1 |
| Zoja, C | 1 |
| Rottoli, D | 1 |
| Foray, C | 1 |
| Fiordaliso, F | 1 |
| Guerrini, U | 1 |
| Tremoli, E | 2 |
| Sironi, L | 2 |
| Gelosa, P | 2 |
| Balakumar, P | 1 |
| Sambathkumar, R | 1 |
| Mahadevan, N | 1 |
| Muhsinah, AB | 1 |
| Alsayari, A | 1 |
| Venkateswaramurthy, N | 1 |
| Dhanaraj, SA | 1 |
| Kostapanos, MS | 1 |
| Florentin, M | 1 |
| Elisaf, MS | 1 |
| Attridge, RL | 1 |
| Frei, CR | 1 |
| Ryan, L | 1 |
| Koeller, J | 1 |
| Linn, WD | 1 |
| Hu, Z | 1 |
| Huang, S | 1 |
| Wu, Y | 1 |
| Su, D | 1 |
| Tao, Y | 1 |
| Fu, P | 1 |
| Zhang, X | 2 |
| Peng, Z | 1 |
| Zhang, S | 1 |
| Yang, Y | 1 |
| Saito, T | 3 |
| Matsunaga, A | 3 |
| Ito, K | 1 |
| Nakashima, H | 2 |
| Ighodaro, I | 1 |
| Eric, OK | 1 |
| Adebayo, O | 1 |
| Salgueiro, G | 1 |
| Beltrán, LM | 1 |
| Torres, RJ | 1 |
| Puig, JG | 1 |
| Weng, H | 1 |
| Endo, K | 1 |
| Iwai, N | 1 |
| Lv, J | 1 |
| Liu, SY | 1 |
| Liang, PF | 1 |
| Feng, M | 1 |
| Zhang, LL | 1 |
| Xu, AP | 1 |
| Cheng, R | 1 |
| Ding, L | 1 |
| He, X | 1 |
| Takahashi, Y | 1 |
| Ma, JX | 1 |
| Shin, SJ | 2 |
| Lim, JH | 2 |
| Chung, S | 2 |
| Youn, DY | 1 |
| Chung, HW | 2 |
| Kim, HW | 2 |
| Lee, JH | 1 |
| Chang, YS | 2 |
| Park, CW | 2 |
| Hou, X | 1 |
| Shen, YH | 1 |
| Wang, F | 1 |
| Zhang, C | 1 |
| Bu, P | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Nobili, E | 1 |
| Cimino, M | 1 |
| Udani, SM | 1 |
| Bakris, GL | 1 |
| Zhou, Y | 1 |
| Kong, X | 1 |
| Zhao, P | 1 |
| Yang, H | 1 |
| Miao, J | 1 |
| Ding, J | 1 |
| Guan, Y | 1 |
| Mori, K | 1 |
| Mukoyama, M | 1 |
| Nakao, K | 1 |
| Kim, MY | 1 |
| Choi, BS | 1 |
| Kim, YS | 1 |
| Samra, M | 1 |
| Abcar, AC | 1 |
| Ieiri, N | 1 |
| Hotta, O | 1 |
| Taguma, Y | 1 |
| Muller, DN | 1 |
| Theuer, J | 1 |
| Shagdarsuren, E | 1 |
| Kaergel, E | 1 |
| Honeck, H | 1 |
| Park, JK | 1 |
| Markovic, M | 1 |
| Barbosa-Sicard, E | 1 |
| Dechend, R | 1 |
| Wellner, M | 1 |
| Kirsch, T | 1 |
| Fiebeler, A | 1 |
| Rothe, M | 1 |
| Haller, H | 1 |
| Luft, FC | 1 |
| Schunck, WH | 1 |
| Angeles, C | 1 |
| Lane, BP | 1 |
| Miller, F | 1 |
| Nord, EP | 1 |
| Schech, S | 1 |
| Graham, D | 1 |
| Staffa, J | 1 |
| Andrade, SE | 1 |
| La Grenade, L | 1 |
| Burgess, M | 1 |
| Blough, D | 1 |
| Stergachis, A | 1 |
| Chan, KA | 1 |
| Platt, R | 1 |
| Shatin, D | 1 |
| Pierno, S | 1 |
| Didonna, MP | 1 |
| Cippone, V | 1 |
| De Luca, A | 1 |
| Pisoni, M | 1 |
| Frigeri, A | 1 |
| Nicchia, GP | 1 |
| Svelto, M | 1 |
| Chiesa, G | 1 |
| Sirtori, C | 1 |
| Scanziani, E | 1 |
| Rizzo, C | 1 |
| De Vito, D | 1 |
| Conte Camerino, D | 1 |
| McQuade, CR | 1 |
| Griego, J | 1 |
| Anderson, J | 1 |
| Pai, AB | 1 |
| Harvengt, C | 1 |
| Desager, JP | 1 |
| Broeders, N | 1 |
| Knoop, C | 1 |
| Antoine, M | 1 |
| Tielemans, C | 1 |
| Abramowicz, D | 1 |
| Lipscombe, J | 2 |
| Lewis, GF | 1 |
| Cattran, D | 1 |
| Bargman, JM | 2 |
| Tsimihodimos, V | 1 |
| Kakafika, A | 1 |
| Elisaf, M | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
6 reviews available for fenofibrate and Kidney Diseases
| Article | Year |
|---|---|
Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits.
Topics: Animals; Cardiovascular Diseases; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Kidney D | 2019 |
Fenofibrate and the kidney: an overview.
Topics: Creatinine; Dose-Response Relationship, Drug; Fenofibrate; Glomerular Filtration Rate; Humans; Hypol | 2013 |
Fenofibrate-associated nephrotoxicity: a review of current evidence.
Topics: Animals; Clinical Trials as Topic; Fenofibrate; Humans; Hypolipidemic Agents; Kidney Diseases; Retro | 2013 |
Topics in lipoprotein glomerulopathy: an overview.
Topics: Apolipoprotein E2; Apolipoproteins E; Fenofibrate; Founder Effect; Humans; Hypertriglyceridemia; Kid | 2014 |
[New evolution in lipoprotein glomerulopathy].
Topics: Animals; Apolipoproteins E; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Kidney | 2013 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
30 other studies available for fenofibrate and Kidney Diseases
| Article | Year |
|---|---|
The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypolipidemic Agents; Kidn | 2019 |
Effects of fenofibrate therapy on renal function in primary gout patients.
Topics: Creatinine; Drug Monitoring; Electronic Health Records; Female; Fenofibrate; Gout; Humans; Hypolipid | 2021 |
Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.
Topics: Animals; Benzamides; Cell Line; Coenzyme A Ligases; Dioxoles; Epithelial Cells; Fatty Acids; Fenofib | 2018 |
Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection.
Topics: Acyl-CoA Dehydrogenase; Animals; Cardiomegaly; Cellular Senescence; Fenofibrate; Gene Expression; Hy | 2018 |
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
Topics: Adolescent; Adult; Aged; Apolipoprotein E2; Biomarkers; Biopsy; Case-Control Studies; China; Creatin | 2014 |
Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis.
Topics: Apolipoprotein E2; Female; Fenofibrate; Humans; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; | 2014 |
Interactions of PPAR α and GLUT4 in DOCA/salt-induced renal injury in mice.
Topics: Animals; Desoxycorticosterone Acetate; Disease Models, Animal; Fenofibrate; Glucose Transporter Type | 2013 |
Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia.
Topics: Adult; Creatinine; Female; Fenofibrate; Gout; Humans; Hypertriglyceridemia; Hyperuricemia; Kidney; K | 2014 |
Pex11a deficiency is associated with a reduced abundance of functional peroxisomes and aggravated renal interstitial lesions.
Topics: Animals; Disease Models, Animal; Fatty Acids; Female; Fenofibrate; Fibrosis; Hypertension; Hypolipid | 2014 |
Protective effect of Fenofibrate in renal ischemia reperfusion injury: Involved in suppressing kinase 2 (JAK2)/transcription 3 (STAT3)/p53 signaling activation.
Topics: Animals; Cytoprotection; Fenofibrate; Janus Kinase 2; Kidney; Kidney Diseases; Kidney Function Tests | 2015 |
Interaction of PPARα With the Canonic Wnt Pathway in the Regulation of Renal Fibrosis.
Topics: Animals; beta Catenin; Blotting, Western; Cells, Cultured; Diabetic Nephropathies; Fenofibrate; Fibr | 2016 |
Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats.
Topics: Adiponectin; Adipose Tissue; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Bloo | 2009 |
PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity.
Topics: Animals; Antioxidants; Collagen; Fenofibrate; Hypertension; Kidney Diseases; Male; MAP Kinase Kinase | 2010 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Do fibrates truly preserve kidney function?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Humans; Kidney; Kidney Diseases | 2011 |
Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury.
Topics: Animals; Apoptosis; Caspase 3; Cell Line; Cytoprotection; Disease Models, Animal; Doxorubicin; Fenof | 2011 |
PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice.
Topics: Animals; Apoptosis; Caspase 3; Cytoprotection; Disease Models, Animal; Doxorubicin; Fenofibrate; Kid | 2011 |
High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway.
Topics: Animals; Apoptosis; Blotting, Western; Diet, High-Fat; Fenofibrate; Forkhead Box Protein O3; Forkhea | 2012 |
False estimates of elevated creatinine.
Topics: Creatinine; Diagnosis, Differential; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Hyperl | 2012 |
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Drug Combinations; Eicosapentaenoic Acid; Female | 2003 |
A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.
Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified | 2004 |
Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.
Topics: Adult; Biopsy; Female; Fenofibrate; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Transplant | 2004 |
Risk factors for statin-associated rhabdomyolysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Drug Therapy, Combin | 2007 |
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.
Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response | 2006 |
Elevated serum creatinine levels associated with fenofibrate therapy.
Topics: Chronic Disease; Creatinine; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Kidney | 2008 |
[Pharmacokinetics of fenofibrate in man (author's transl)].
Topics: Colestipol; Drug Interactions; Fenofibrate; Half-Life; Humans; Hyperlipidemias; Hypolipidemic Agents | 1980 |
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidem | 2000 |
Deterioration in renal function associated with fibrate therapy.
Topics: Adult; Aged; Creatinine; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Ki | 2001 |
Fibrate treatment can increase serum creatinine levels.
Topics: Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Ki | 2001 |
Fibrate-induced increase in blood urea and creatinine.
Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyp | 2001 |